Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR 1,236.30
+16.30 (1.34%)
May 15, 2025, 3:29 PM IST
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B INR with 16.61% growth. Dr. Reddy's Laboratories had revenue of 85.06B in the quarter ending March 31, 2025, with 20.09% growth.
Revenue
325.54B
Revenue Growth
+16.61%
P/S Ratio
3.16
Revenue / Employee
12.04M
Employees
27,048
Market Cap
1,028.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Dr. Reddy's Laboratories News
- 6 hours ago - Dr. Reddy's Continues To Be A Good Buy At Current Valuation - Seeking Alpha
- 2 days ago - JP Morgan, Goldman Sachs & more: Top stocks on brokers' radar for today - The Times of India
- 3 days ago - Generics won't be affected by Trump's pricing policy, says Dr. Reddy's - CNBC
- 3 days ago - Dr. Reddy's (RDY) Surpasses Q4 2025 Earnings and Revenue Expectations - GuruFocus
- 3 days ago - Dr. Reddy’s Laboratories shares surge 3% as Nomura reaffirms Buy’ rating, raising target price to Rs 1,575 - Business Upturn
- 3 days ago - Dr. Reddy's GAAP EPS of $0.22 beats by $0.02, revenue of $996M beats by $13.8M - Seeking Alpha
- 3 days ago - Stocks to watch on brokerages: Pidilite, Swiggy, Thermax among top shares to buy; mixed calls on Dr. Reddy’s, ABB [May 12] - Business Upturn
- 6 days ago - Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript - Seeking Alpha